Is DaVita Inc. (DVA) A Good Stock To Buy?

Core Thesis - DaVita Inc. is viewed positively by analysts, with shares trading at $154.79 and trailing and forward P/E ratios of 16.01 and 11.36 respectively [1] Financial Performance - DaVita generated $12.9 billion in revenue for 2025, with a modest organic growth of 0.6% and an adjusted operating profit of $2.094 billion [3] - The company maintains a strong financial quality with an adjusted operating margin of approximately 16.2% [4] Challenges - The primary challenge for DaVita is the decline in patient volume, with dialysis treatments decreasing by 1.1% during the year, which directly impacts revenue and profitability [4] - Revenue growth in the U.S. dialysis division was primarily driven by a 4.7% increase in revenue per treatment rather than an increase in patient volumes [5] Strategic Initiatives - Management is optimistic about clinical initiatives aimed at reducing patient mortality, which could potentially restore about 2% annual volume growth, although benefits may not be realized until around 2029 [5] - The Integrated Kidney Care (IKC) segment became profitable in 2025 with $22 million in operating profit, reflecting improved performance in value-based contracts rather than significant volume growth [6] - DaVita is pursuing a $200 million minority investment in Elara Caring to enhance patient outcomes and integrated care capabilities [6] Investment Outlook - The investment thesis is uncertain as success relies heavily on clinical outcomes rather than traditional operational improvements [7] - DaVita generates strong free cash flow of about $1 billion annually and engages in aggressive share repurchases, but projected EPS growth is largely attributed to buybacks rather than business expansion [7] - The company is characterized as financially strong but fundamentally defensive, with long-term performance contingent on the success of clinical initiatives to reverse declining patient volumes [7]